Roots of imatinib resistance: A question of self-renewal?

Drug Resistance Updates

Volumn 10, Issue 4-5, 2007, Pages 152-161

  Burchert, Andreas ^a  

^a UNIVERSITY HOSPITAL MARBURG   (Germany)

Author keywords

BCR ABL; BCR ABL independent drug resistance; CML; Imatinib resistance; Ph+ ALL; Self renewal

Indexed keywords

DASATINIB; IMATINIB; NILOTINIB; PROTEIN BCL 2; PROTEIN P53; PROTEIN TYROSINE KINASE;

ACUTE LYMPHOCYTIC LEUKEMIA; ARTICLE; CELL RENEWAL; ENZYME INHIBITION; FUSION GENE; GENE MUTATION; HUMAN; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; STEM CELL;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HUMANS; MODELS, BIOLOGICAL; MUTATION; PIPERAZINES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN-TYROSINE KINASES; PYRIMIDINES;

EID: 34548830437     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drup.2007.06.001     Document Type: Article

References (104)

1. Azam M., Latek R.-R., and Daley G.-Q. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 112 (2003) 831-843
2. Biernaux C., Loos M., Sels A., Huez G., and Stryckmans P. Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. Blood 86 (1995) 3118-3122
3. Bose S., Deininger M., Gora-Tybor J., Goldman J.-M., and Melo J.-V. The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood 92 (1998) 3362-3367
4. Branford S., Rudzki Z., Walsh S., Grigg A., Arthur C., Taylor K., Herrmann R., Lynch K.P., and Hughes T.P. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 99 (2002) 3472-3475
5. Branford S., Rudzki Z., Walsh S., Parkinson I., Grigg A., Szer J., Taylor K., Herrmann R., Seymour J.-F., Arthur C., Joske D., Lynch K., and Hughes T. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 102 (2003) 276-283
6. Buchdunger E., Zimmermann J., Mett H., Meyer T., Muller M., Druker B.-J., and Lydon N.-B. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylamino-pyrimidine derivative. Cancer Res. 56 (1996) 100-104
7. Burchert A., Cai D., Hofbauer L.-C., Samuelsson M.-K., Slater E.-P., Duyster J., Ritter M., Hochhaus A., Muller R., Eilers M., Schmidt M., and Neubauer A. Interferon consensus sequence binding protein (ICSBP; IRF-8) antagonizes BCR/ABL and down-regulates bcl-2. Blood 103 (2004) 3480-3489
8. Burchert A., Wang Y., Cai D., von Bubnoff N., Paschka P., Muller-Brusselbach S., Ottmann O.-G., Duyster J., Hochhaus A., and Neubauer A. Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development. Leukemia 19 (2005) 1774-1782
9. Burgess M.-R., Skaggs B.-J., Shah N.-P., Lee F.-Y., and Sawyers C.-L. Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 3395-3400
10. Castor A., Nilsson L., Astrand-Grundstrom I., Buitenhuis M., Ramirez C., Anderson K., Strombeck B., Garwicz S., Bekassy A.-N., Schmiegelow K., Lausen B., Hokland P., Lehmann S., Juliusson G., Johansson B., and Jacobsen S.E. Distinct patterns of hematopoietic stem cell involvement in acute lymphoblastic leukemia. Nat. Med. 11 (2005) 630-637
11. Chu S., Holtz M., Gupta M., and Bhatia R. BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells. Blood 103 (2004) 3167-3174
12. Chu S., Xu H., Shah N.-P., Snyder D.-S., Forman S.J., Sawyers C.-L., and Bhatia R. Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment. Blood 105 (2005) 2093-2098
13. Copland M., Hamilton A., Elrick L.-J., Baird J.-W., Allan E.-K., Jordanides N., Barow M., Mountford J.-C., and Holyoake T.-L. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 107 (2006) 4532-4539
14. Cortes J., O'Brien S., and Kantarjian H. Discontinuation of imatinib therapy after achieving a molecular response. Blood 104 (2004) 2204-2205
15. Crossman L.-C., Druker B.-J., Deininger M.-W., Pirmohamed M., Wang L., and Clark R.E. hOCT 1 and resistance to imatinib. Blood 106 (2005) 1133-1134 (author reply 1134)
16. Dai Y., Rahmani M., Corey S.-J., Dent P., and Grant S. A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2. J. Biol. Chem. 279 (2004) 34227-34239
17. Deininger M., Buchdunger E., and Druker B.-J. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105 (2005) 2640-2653
18. Dombret H., Ottmann O.-G., Rosti G., Simonsson B., Larson R.-A., Gollerkeri A., Apanovitch A., Radich J., and Coutre S. Dasatinib (SPRYCEL(R)) in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia who are imatinib-resistant or -intolerant: updated results from the CA180-015 'START-L' Study. ASH Ann. Meet. Abstr. 108 (2006) 286
19. Donato N.-J., Wu J.-Y., Stapley J., Gallick G., Lin H., Arlinghaus R., and Talpaz M. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 101 (2003) 690-698
20. Donato N.-J., Wu J.-Y., Stapley J., Lin H., Arlinghaus R., Aggarwal B.B., Shishodia S., Albitar M., Hayes K., Kantarjian H., and Talpaz M. Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res. 64 (2004) 672-677
21. Druker B.-J., Tamura S., Buchdunger E., Ohno S., Segal G.-M., Fanning S., Zimmermann J., and Lydon N.B. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2 (1996) 561-566
22. Druker B.-J., Sawyers C.-L., Kantarjian H., Resta D.-J., Reese S.-F., Ford J.-M., Capdeville R., and Talpaz M. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 344 (2001) 1038-1042
23. Druker B.J., Guilhot F., O'Brien S.G., Gathmann I., Kantarjian H., Gattermann N., et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 355 (2006) 2408-2417
24. Fialkow P.-J., Denman A.-M., Jacobson R.-J., and Lowenthal M.-N. Chronic myelocytic leukaemia. Origin of some lymphocytes from leukemic stem cells. J. Clin. Invest. 62 (1978) 815-823
25. Frank O., Brors B., Fabarius A., Li L., Haak M., Merk S., Schwindel U., Zheng C., Muller M.-C., Gretz N., Hehlmann R., Hochhaus A., and Seifarth W. Gene expression signature of primary imatinib-resistant chronic myeloid leukemia patients. Leukemia 20 (2006) 1400-1407
26. Giles F.-J., Cortes J., Jones D., Bergstrom D., Kantarjian H., and Freedman S.J. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood 109 (2007) 500-502
27. Golas J.-M., Arndt K., Etienne C., Lucas J., Nardin D., Gibbons J., Frost P., Ye F., Boschelli D.-H., and Boschelli F. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res. 63 (2003) 375-381
28. Gorre M.-E., Mohammed M., Ellwood K., Hsu N., Paquette R., Rao P.-N., and Sawyers C.-L. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293 (2001) 876-880
29. Graham S.-M., Jorgensen H.-G., Allan E., Pearson C., Alcorn M.-J., Richmond L., and Holyoake T.-L. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 99 (2002) 319-325
30. Griswold I.-J., MacPartlin M., Bumm T., Goss V.-L., O'Hare T., Lee K.-A., Corbin A.-S., Stoffregen E.-P., Smith C., Johnson K., Moseson E.-M., Wood L.-J., Polakiewicz R.-D., Druker B.-J., and Deininger M.W. Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib. Mol. Cell. Biol. 26 (2006) 6082-6093
31. Guilhot F., Apperley J., Kim D.-W., Bullorsky E.-O., Baccarani M., Roboz G.-J., Amadori S., de Souza C.-A., Lipton J.-H., Hochhaus A., Heim D., Larson R.-A., Branford S., Muller M.-C., Agarwal P., Gollerkeri A., and Talpaz M. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood 109 (2007) 4143-4150
32. Hochhaus A., Kreil S., Corbin A., La Rosee P., Lahaye T., Berger U., Cross N.-C., Linkesch W., Druker B.-J., Hehlmann R., Gambacorti-Passerini C., Corneo G., and D'Incalci M. Roots of clinical resistance to STI-571 cancer therapy. Science 293 (2001) 2163
33. Hochhaus A., Kreil S., Corbin A.-S., La Rosee P., Muller M.-C., Lahaye T., Hanfstein B., Schoch C., Cross N.-C., Berger U., Gschaidmeier H., Druker B.-J., and Hehlmann R. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 16 (2002) 2190-2196
34. Hofmann W.-K., de Vos S., Elashoff D., Gschaidmeier H., Hoelzer D., Koeffler H.-P., and Ottmann O.-G. Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression study. Lancet 359 (2002) 481-486
35. Hofmann W.-K., Jones L.-C., Lemp N.-A., de Vos S., Gschaidmeier H., Hoelzer D., Ottmann O.-G., and Koeffler H.-P. Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. Blood 99 (2002) 1860-1862
36. Holtschke T., Lohler J., Kanno Y., Fehr T., Giese N., Rosenbauer F., Lou J., Knobeloch K.-P., Gabriele L., Waring J.-F., Bachmann M.-F., Zinkernagel R.-M., Morse III H.-C., Ozato K., and Horak I. Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. Cell 87 (1996) 307-317
37. Holyoake T., Jiang X., Eaves C., and Eaves A. Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. Blood 94 (1999) 2056-2064
38. Horita M., Andreu E.-J., Benito A., Arbona C., Sanz C., Benet I., Prosper F., and Fernandez-Luna J.-L. Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL. J. Exp. Med. 191 (2000) 977-984
39. Hu Y., Liu Y., Pelletier S., Buchdunger E., Warmuth M., Fabbro D., Hallek M., Van Etten R.-A., and Li S. Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukaemia. Nat. Genet. 36 (2004) 453-461
40. Hu Y., Swerdlow S., Duffy T.-M., Weinmann R., Lee F.-Y., and Li S. Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 16870-16875
41. Hughes T.-P., Kaeda J., Branford S., Rudzki Z., Hochhaus A., Hensley M.L., Gathmann I., Bolton A.-E., van Hoomissen I.-C., Goldman J.-M., and Radich J.-P. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N. Engl. J. Med. 349 (2003) 1423-1432
42. Huntly B.-J., and Gilliland D.-G. Cancer biology: summing up cancer stem cells. Nature 435 (2005) 1169-1170
43. Huntly B.-J., Shigematsu H., Deguchi K., Lee B.-H., Mizuno S., Duclos N., Rowan R., Amaral S., Curley D., Williams I.-R., Akashi K., and Gilliland D.-G. MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell 6 (2004) 531-533
44. Illmer T., Schaich M., Platzbecker U., Freiberg-Richter J., Oelschlagel U., von Bonin M., Pursche S., Bergemann T., Ehninger G., and Schleyer E. P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia 18 (2004) 401-408
45. Jabbour E., Kantarjian H., Jones D., Talpaz M., Bekele N., O'Brien S., Zhou X., Luthra R., Garcia-Manero G., Giles F., Rios M.-B., Verstovsek S., and Cortes J. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 20 (2006) 1767-1773
46. Jacobs J.-J., Kieboom K., Marino S., DePinho R.-A., and van Lohuizen M. The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature 397 (1999) 164-168
47. Jamieson C.-H., Ailles L.-E., Dylla S.-J., Muijtjens M., Jones C., Zehnder J.-L., Gotlib J., Li K., Manz M.-G., Keating A., Sawyers C.-L., and Weissman I.-L. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N. Engl. J. Med. 351 (2004) 657-667
48. Jiang X., Saw K.-M., Eaves A., and Eaves C. Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells. J. Natl. Cancer Inst. 99 (2007) 680-693
49. Jiang X., Zhao Y., Smith C., Gasparetto M., Turhan A., Eaves A., and Eaves C. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia 21 (2007) 926-935
50. Jordan C.-T., Guzman M.-L., and Noble M. Cancer stem cells. N. Engl. J. Med. 355 (2006) 1253-1261
51. Jorgensen H.-G., Allan E.-K., Jordanides N.-E., Mountford J.-C., and Holyoake T.-L. Nilotinib exerts equipotent anti-proliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. Blood 109 (2007) 4016-4019
52. Kantarjian H., Giles F., Wunderle L., Bhalla K., O'Brien S., Wassmann B., et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N. Engl. J. Med. 354 (2006) 2542-2551
53. Kantarjian H., O'Brien S., Talpaz M., Borthakur G., Ravandi F., Faderl S., Verstovsek S., Rios M.-B., Shan J., Giles F., and Cortes J. Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure. Cancer 109 (2007) 1556-1560
54. Kimura S., Naito H., Segawa H., Kuroda J., Yuasa T., Sato K., et al. NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood 106 (2005) 3948-3954
55. Koptyra M., Falinski R., Nowicki M.-O., Stoklosa T., Majsterek I., Nieborowska-Skorska M., Blasiak J., and Skorski T. BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance. Blood 108 (2006) 319-327
56. Lange T., Park B., Willis S.-G., and Deininger M.-W. BCR-ABL kinase domain mutations in chronic myeloid leukemia: not quite enough to cause resistance to imatinib therapy?. Cell Cycle 4 (2005) 1761-1766
57. Lee S., Kim Y.-J., Min C.-K., Kim H.-J., Eom K.-S., Kim D.-W., Lee J.-W., Min W.-S., and Kim C.-C. The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 105 (2005) 3449-3457
58. Li S., Ilaria Jr. R.-L., Million R.-P., Daley G.-Q., and Van Etten R.-A. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J. Exp. Med. 189 (1999) 1399-1412
59. Lowe S.-W., Cepero E., and Evan G. Intrinsic tumour suppression. Nature 432 (2004) 307-315
60. Miething C., Grundler R., Mugler C., Brero S., Hoepfl J., Geigl J., Speicher M.-R., Ottmann O.-G., Peschel C., and Duyster J. Retroviral insertional mutagenesis identifies RUNX genes involved in chronic myeloid leukemia disease persistence under imatinib treatment. Proc. Natl. Acad. Sci. U.S.A. 104 (2007) 4594-4599
61. Mishra S., Zhang B., Cunnick J.-M., Heisterkamp N., and Groffen J. Resistance to imatinib of bcr/abl p190 lymphoblastic leukemia cells. Cancer Res. 66 (2006) 5387-5393
62. Mohty M., Yong A.-S., Szydlo R.-M., Apperley J.-F., and Melo J.-V. The polycomb group BMI-1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia. Blood 110 (2007) 380-383
63. Nicolini F.-E., Corm S., Le Q.-H., Sorel N., Hayette S., Bories D., et al. Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP). Leukemia 20 (2006) 1061-1066
64. O'Hare T., Walters D.-K., Stoffregen E.-P., Jia T., Manley P.-W., Mestan J., Cowan-Jacob S.-W., Lee F.-Y., Heinrich M.-C., Deininger M.W., and Druker B.J. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 65 (2005) 4500-4505
65. O'Hare T., Walters D.-K., Stoffregen E.-P., Sherbenou D.-W., Heinrich M.-C., Deininger M.-W., and Druker B.-J. Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib. Clin. Cancer Res. 11 (2005) 6987-6993
66. Ottmann O.-G., Druker B.-J., Sawyers C.-L., Goldman J.-M., Reiffers J., Silver R.-T., et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 100 (2002) 1965-1971
67. Park I.-K., Qian D., Kiel M., Becker M.-W., Pihalja M., Weissman I.-L., Morrison S.-J., and Clarke M.-F. Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature 423 (2003) 302-305
68. Pear W.-S., Miller J.-P., Xu L., Pui J.-C., Soffer B., Quackenbush R.-C., Pendergast A.-M., Bronson R., Aster J.-C., Scott M.-L., and Baltimore D. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210bcr/abl-transduced bone marrow. Blood 92 (1998) 3780-3792
69. Pfeifer H., Wassmann B., Pavlova A., Wunderle L., Oldenburg J., Binckebanck A., Lange T., Hochhaus A., Wystub S., Bruck P., Hoelzer D., and Ottmann O.-G. Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 110 (2007) 727-734
70. Ptasznik A., Nakata Y., Kalota A., Emerson S.-G., and Gewirtz A.-M. Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells. Nat. Med. 10 (2004) 1187-1189
71. Puttini M., Coluccia A.-M., Boschelli F., Cleris L., Marchesi E., Donella-Deana A., Ahmed S., Redaelli S., Piazza R., Magistroni V., Andreoni F., Scapozza L., Formelli F., and Gambacorti-Passerini C. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer Res. 66 (2006) 11314-11322
72. Reya T., Morrison S.-J., Clarke M.-F., and Weissman I.-L. Stem cells, cancer, and cancer stem cells. Nature 414 (2001) 105-111
73. Roche-Lestienne C., Soenen-Cornu V., Grardel-Duflos N., Lai J.-L., Philippe N., Facon T., Fenaux P., and Preudhomme C. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 100 (2002) 1014-1018
74. Roeder I., Horn M., Glauche I., Hochhaus A., Mueller M.-C., and Loeffler M. Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications. Nat. Med. 12 (2006) 1181-1184
75. Samanta A.-K., Lin H., Sun T., Kantarjian H., and Arlinghaus R.-B. Janus kinase 2: a critical target in chronic myelogenous leukemia. Cancer Res. 66 (2006) 6468-6472
76. Sawyers C.-L., Hochhaus A., Feldman E., Goldman J.-M., Miller C.-B., Ottmann O.-G., et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 99 (2002) 3530-3539
77. Shah N.-P., Nicoll J.-M., Nagar B., Gorre M.-E., Paquette R.-L., Kuriyan J., and Sawyers C.-L. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2 (2002) 117-125
78. Shah N.-P., Tran C., Lee F.-Y., Chen P., Norris D., and Sawyers C.-L. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305 (2004) 399-401
79. Sherbenou D.-W., Wong M.-J., Humayun A., McGreevey L.-S., Harrell P., Yang R., Mauro M., Heinrich M.-C., Press R.-D., Druker B.-J., and Deininger M.-W. Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib. Leukemia 21 (2007) 489-493
80. Sherr C.-J. Divorcing ARF and p53: an unsettled case. Nat. Rev. Cancer 6 (2006) 663-673
81. Skorski T. BCR/ABL regulates response to DNA damage: the role in resistance to genotoxic treatment and in genomic instability. Oncogene 21 (2002) 8591-8604
82. Soverini S., Martinelli G., Rosti G., Bassi S., Amabile M., Poerio A., et al. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA working party on chronic myeloid leukemia. J. Clin. Oncol. 23 (2005) 4100-4109
83. Soverini S., Colarossi S., Gnani A., Rosti G., Castagnetti F., Poerio A., et al. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA working party on chronic myeloid leukemia. Clin. Cancer Res. 12 (2006) 7374-7379
84. Soverini S., Martinelli G., Colarossi S., Gnani A., Castagnetti F., Rosti G., et al. Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia. J. Clin. Oncol. 24 (2006) e51-e52
85. Sun X., Layton J.-E., Elefanty A., and Lieschke G.-J. Comparison of effects of the tyrosine kinase inhibitors AG957, AG490, and STI571 on BCR-ABL-expressing cells, demonstrating synergy between AG490 and STI571. Blood 97 (2001) 2008-2015
86. Takahashi N., Miura I., Saitoh K., and Miura A.-B. Lineage involvement of stem cells bearing the Philadelphia chromosome in chronic myeloid leukemia in the chronic phase as shown by a combination of fluorescence-activated cell sorting and fluorescence in situ hybridization. Blood 92 (1998) 4758-4763
87. Talpaz M., Silver R.-T., Druker B.-J., Goldman J.-M., Gambacorti-Passerini C., Guilhot F., et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 99 (2002) 1928-1937
88. Talpaz M., Shah N.-P., Kantarjian H., Donato N., Nicoll J., Paquette R., Cortes J., O'Brien S., Nicaise C., Bleickardt E., Blackwood-Chirchir M.-A., Iyer V., Chen T.-T., Huang F., Decillis A.-P., and Sawyers C.-L. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N. Engl. J. Med. 354 (2006) 2531-2541
89. Thomas J., Wang L., Clark R.-E., and Pirmohamed M. Active transport of imatinib into and out of cells: implications for drug resistance. Blood 104 (2004) 3739-3745
90. Uchida M., Watanabe T., Kunitama M., Mori M., Kikuchi S., Yoshida K., Kirito K., Nagai T., Ozawa K., and Komatsu N. Erythropoietin overcomes imatinib-induced apoptosis and induces erythroid differentiation in TF-1/bcr-abl cells. Stem Cells 22 (2004) 609-616
91. Villuendas R., Steegmann J.-L., Pollan M., Tracey L., Granda A., Fernandez-Ruiz E., Casado L.-F., Martinez J., Martinez P., Lombardia L., Villalon L., Odriozola J., and Piris M.A. Identification of genes involved in imatinib resistance in CML: a gene-expression profiling approach. Leukemia 20 (2006) 1047-1054
92. von Bubnoff N., Veach D.-R., van der Kuip H., Aulitzky W.-E., Sanger J., Seipel P., Bornmann W.-G., Peschel C., Clarkson B., and Duyster J. A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor. Blood 105 (2005) 1652-1659
93. von Bubnoff N., Manley P.-W., Mestan J., Sanger J., Peschel C., and Duyster J. Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107). Blood 108 (2006) 1328-1333
94. Wang J.C., and Dick J.-E. Cancer stem cells: lessons from leukemia. Trends Cell Biol. 15 (2005) 494-501
95. Wang Y., Cai D., Brendel C., Barett C., Erben P., Manley P.-W., Hochhaus A., Neubauer A., and Burchert A. Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL+ progenitors via JAK-2/STAT-5 pathway activation. Blood 109 (2007) 2147-2155
96. Warmuth M., Simon N., Mitina O., Mathes R., Fabbro D., Manley P.-W., Buchdunger E., Forster K., Moarefi I., and Hallek M. Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases. Blood 101 (2003) 664-672
97. Wassmann B., Pfeifer H., Goekbuget N., Beelen D.-W., Beck J., Stelljes M., et al. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 108 (2006) 1469-1477
98. Weisberg E., Manley P.-W., Breitenstein W., Bruggen J., Cowan-Jacob S.-W., Ray A., Huntly B., Fabbro D., Fendrich G., Hall-Meyers E., Kung A.-L., Mestan J., Daley G.-Q., Callahan L., Catley L., Cavazza C., Azam M., Neuberg D., Wright R.-D., Gilliland D.-G., and Griffin J.-D. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7 (2005) 129-141
99. Weisberg E., Manley P.-W., Cowan-Jacob S.-W., Hochhaus A., and Griffin J.D. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat. Rev. Cancer 7 (2007) 345-356
100. Wendel H.-G., de Stanchina E., Cepero E., Ray S., Emig M., Fridman J.-S., Veach D.-R., Bornmann W.G., Clarkson B., McCombie W.-R., Kogan S.C., Hochhaus A., and Lowe S.-W. Loss of p53 impedes the antileukemic response to BCR-ABL inhibition. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 7444-7449
101. Williams R.-T., Roussel M.-F., and Sherr C.-J. Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 6688-6693
102. Willis S.-G., Lange T., Demehri S., Otto S., Crossman L., Niederwieser D., Stoffregen E.-P., McWeeney S., Kovacs I., Park B., Druker B.-J., and Deininger M.-W. High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood 106 (2005) 2128-2137
103. Xie S., Wang Y., Liu J., Sun T., Wilson M.-B., Smithgall T.-E., and Arlinghaus R.-B. Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation. Oncogene 20 (2001) 6188-6195
104. Yokota A., Kimura S., Masuda S., Ashihara E., Kuroda J., Sato K., Kamitsuji Y., Kawata E., Deguchi Y., Urasaki Y., Terui Y., Ruthardt M., Ueda T., Hatake K., Inui K., and Maekawa T. INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity. Blood 109 (2007) 306-314